Q2 2025 Bruker Corp Earnings Call

Taki followed by zero.

After today's presentation, there will be an opportunity to ask questions. You may press "Start," then 1 on the attached tone phone.

To withdraw your questions, please press star, then 2. Please note, this event is being recorded. I would now like to turn the conference over to Joe Kostka, Director of Investor Relations. Please go ahead.

Good morning. I would like to welcome everyone to Brewer Corporation, second quarter, 2025 earnings conference call.

My name is Joe Costa, and I am the Director of Investor Relations at Bruker. Joining me on today's call are our President and CEO, Frank Lin, and our EVP and CFO, Gerald Herman.

In addition to the earnings release, we issued earlier today. During today's conference call, we will be referencing a slide presentation that can be downloaded from the events and presentation section of brooker's investor relations website.

During today's call, we will be highlighting non-GAAP financial information.

reconciliations of our non-gaap to gaap financial, measures are included in our earnings release, and our posted on our website at IR brooker.com,

Before we begin, I would like to reference Bruker's Safe Harbor statement, which is shown on slide 2 of the presentation.

During this conference call, we will make forward-looking statements regarding future events in the financial and operational performance of the company that involve risks and uncertainties.

Including those related to acquisitions, geopolitical risks, tariffs, the foreign currency market, demand, or supply chains.

The company's actual results May differ materially from such statements.

Factors that might cause such differences include, but are not limited to, those discussed in today's earnings release and in our Form 10-K for the period ending December 31, 2024, as updated by our other SEC filings, which are available on our website and on the FCC's website.

Also, please note that the following information is based on current business conditions and on our outlook as of today, August 4, 2025.

We do not intend to update our forward-looking statements based on new information, future events, or for other reasons, except as may be required by law, prior to the release of our third quarter of 2025 financial results.

Expected in early November 2025.

You should not rely on these forward-looking statements as necessarily representing our views or Outlook as of any date after today.

We will begin today's call with Frank, providing an overview of our business and updated thoughts and assumptions around the U.S. and global funding environment and tariffs.

Gerald will then cover the financials for the second quarter of 2025 in more detail and share our updated fiscal year 2025 financial outlook.

Now, I'd like to turn the call over to Brooker CEO Frank Lin.

Thank you, Joe, good morning, everyone. And thank you for joining us on today's second quarter 2025 earnings call.

Life science, research, instruments, markets, are under pressure at the moment.

With expected us academic funding headwinds and China stimulus. Delays for high-end research instrumentation.

In addition, global tariffs, pharma pricing, and economic uncertainty in the second quarter have delayed biopharma and industrial research instrumentation investments.

This resulted in lower-than-anticipated bookings and revenues in the second quarter.

Our broker scientific instruments or BSI segment book to Bill ratio was in the mid n range in the quarter which was not great but also not too bad.

We anticipate that the third quarter will bring additional visibility on us NIH and NSF funding both for the remainder of fiscal year. 25 as well as for fiscal year, 26 Federal research budgets

We are encouraged by several recent settlements of disputes between major universities and the federal government. We anticipate additional settlements to allow the resumption of grants for important scientific and medical research.

On academic and disease biology research, we believe that our unique post-genomic tools will be in significant demand in all geographies. In particular, this will be the case when China releases its stimulus budgets for high-end medical research instrumentation.

Systems as well as in research and quality control tools for Advanced Materials, clean tech, and semiconductor research and production.

We are observing where U.S. tariffs on Swiss imports will settle, and we anticipate that ultimately it will not be at 39%, the rate communicated last week.

In a worst case scenario for Switzerland, we intend to leverage our other European union, and US factories for products designated for the United States Market.

Broker is poised to resume above market growth, particularly in the Next Generation systems needed for disease, research and Drug Discovery in you of the greater biological complexity revealed by the emerging post-genomic View.

Similarly, the enormous investments in artificial intelligence are very beneficial for advanced and often unique semiconductor metrology tools.

Finally, we have strong positions, and microbiology and infection Diagnostics with an exciting roadmap of medically needed and differentiated capabilities.

Back to our second quarter, the stronger-than-anticipated organic revenue decline.

Coupled with higher us tariffs and stiff currency trade winds from a from a declining US Dollars. Caused margins and profitability to come in below our expectations.

On our first quarter call, we discussed our mitigating price, supply chain, and cost measures, but these take to the Q3 before they fully benefit our operating results.

Today we are announcing a significantly expanded cost savings initiative. That is expected to reduce our annual costs for fiscal year, 2026 by 100 million, to 120 million annualized.

These major cost reduction, reductions affect all parts of our business from supply chain and Manufacturing to our commercial administrative and R&D Investments.

These are difficult but necessary decisions to right-size our cost structure to match the trough demand levels currently seen in the market.

As a result of our weaker second quarter performance, we are lowering our guidance expectations for fiscal year 2025.

We now expect approximately flat constant exchange rate, Revenue growth,

And organic Revenue decline to decline. Minus 2 to minus 4% for the year with a mid teens percentage. Non-gaap EPS decline year-over-year,

In 2025, even in a muted revenue growth scenario in fiscal year 26, it is our intention to deliver very significant margin improvements and double-digit EPS growth, just based on our major cost reduction initiatives.

If there is also a partial growth recovery in advanced life science research and drug discovery tools in fiscal year 2026, then this could provide additional tailwind.

Beyond 2026, we expect to return to our stated goal of organic revenue growth of 200 to 300 basis points above market, which we delivered many years in a row.

And with rapid margin expansion and double-digit EPS growth, once academic trade and economic uncertainty abates.

This is driven by our exceptional innovation in next-generation disease research and bio-pharma drug discovery. Tools for the post-genomic era. This is also driven by other broker-specific growth drivers from semiconductor metrology for the AI revolution to unique applied and diagnostic solutions.

Turning to slide 4 for our Q2 25 performance. As I just detailed in the second quarter of 2025, we faced delays, in many end markets, most notably, biofarma and Industrial, which drove both the top and bottom lines to come in below our expectations.

Percent organic decline at best. Net of intercompany eliminations.

Revenue growth from acquisitions added 3.7%, which implies a constant exchange rate, Crescent revenue decline of 3.3% year-over-year.

To bill in the quarter was in the midpoint n range.

Our second quarter.

Sorry, our second quarter 2025 non-GAAP operating margin was 9%.

A decrease of 480 bibs year-over-year. As lower Revenue, absorption additional Terrace costs and currency. Headwinds were only partially mitigated in Q2 by our earlier cost and pricing actions.

In our second quarter, 25 dilated non-gaap EPS was at 32 cents down 39% from 52 cents. In the second quarter of 2024, on organic Revenue, decline impact of tariffs, and foreign exchange, headwinds Gerald will discuss. The drivers for margins and EPS later in more detail.

Moving to slide 5, our first half $25.

First half organic revenue declined 2.3%, consisting of a 1.4% organic decline in scientific instruments (BSI) and an 11.5% organic decline at best, net of intercompany eliminations.

Our first half 2025 non-gaap growth and operating margins, and gaap and non-gaap, EPS performance are all summarized on slide 5.

Please turn to slide 6 and 7 where we highlight the first half 2025.

Performance of our 3, scientific instruments group, and of our best segments, all on a constant currency and year-over-year basis.

In the first half of 25.

Bio spin group Revenue was 403 million and was roughly flat year-over-year. Bio spin saw contributions from NMR pre-clinical Imaging and lab automation. While the scientific software business was soft.

Biospin saw weakness, in biofarma revenues and softness in orders, both in academic, and applied markets.

For the first half of 25, Kali group, revenue of 566 million increased in the low teens percentage with strong growth in microbiology and infection Diagnostics.

Driven by the maldi biotyper and the Brooker ilec molecular Diagnostics business.

Our applied mass spectrometry business saw robust growth, which offsets some softness in the life science mass spectrometry business.

turn to 11, slide 7 now

First half 25 Brooker. Nano Revenue was 509 million and grew in the low single digits percentage.

Spatial biology contributed to growth in the first half of 2025, while revenues from Advanced X-ray were down year-over-year.

With partially offset by weakness in industrial markets.

Finally first half 25, best revenues declined in the low teams percentage, net of net of intercompany eliminations due to softness in the clinical MRI Market, as well as a strong priority comparison for the research instruments business.

Moving to slide 8, we highlight some of our recent Innovations in the second quarter at azoms obviously in almost unprecedented lineup of new and and and Market changing instruments from our Tim's product line, as well as in Nano LC. I won't go into these in detail in, uh, today. But the significantly enhance our competitive position in traditional bottom-up, proteomics, while also getting us in ushering in a new era of functional proteomics and Proto form analysis with the Tim's Omni. We had very good orders since asms already and finally a very serious play in the in benchtop 40, metabolomics with the Tim's mehtab launched with very high sensitivity. And because of the 4, dimensions and unprecedented annotation continents being very well received in the market,

Let me move to slide 9.

Probably the key theme for today. How are we navigating through this macro and research? Instruments? Weakness.

You are aware of the US academic funding disruption.

Presentation for academic and medical research. China stimulus continues to be delayed Although our customers remain optimistic for release in the second half.

And uh,

In the second quarter, we saw that drug Discovery and Industrial Research. Uh tools saw capex delays and weakness in both of these segments.

We're looking forward to more visibility on what time frames still recover once the terrorists and other items settle in. We also had more tariffs and FX cost headwinds, so um, a lot of headwinds in this second quarter.

We?

Focus on our industry-leading innovation and continue our strategy to re-accelerate growth and enhance market share in the post-genomic era in academic and medical research. But also, very much in biopharma drug discovery tools when they come back.

Very importantly, we're broadly expanding our cost reductions, which we had begun previously, but we're expanding those with a goal of $100 million to $220 million of annualized cost reductions to improve margins and profitability. We're obviously looking for a very significant step up in fiscal year 2026, driven just by the cost reductions and hopefully some emerging recovery in the markets.

Of course, we are seizing New Opportunities and spatial biology. And multiomics are very large growth drivers, even if they're muted at the moment, as well as New Growth drivers in lab automation, scientific software, India improving semiconductor.

Metrology for AI is an incredible opportunity, with emerging growth in European chemical and explosives detection, airport security, and airline security. Finally, our Industrial Research business is focusing on clean tech, batteries, and fusion, and we are adding to our consumables business both organically and inorganically.

so,

To wrap up, the second quarter was a challenging one for Bruker, and we are aggressively executing on our expanded cost reduction initiatives with the goal of delivering strong margin expansion and EPS growth in 2026, even in a flat to low growth scenario.

We are, however, cautiously optimistic for Fiscal Year 2026 partial recovery and point to Bruker's successful track record of rebounding very strongly from previous market disruptions in 2008-2009 and in 2020, from which Bruker emerged with multiple years of double-digit organic revenue growth in each scenario.

We we remain confident that brooker's Innovation, engine will continue to drive differentiated high value, Solutions and attractive markets.

Our culture of disciplined entrepreneurialism and our Bruker management process will position us well for sustained financial success in the years to come.

Let me now turn the call over to our CFO, Gerald Herman, who will review Bruker's Q2 financial performance and updated fiscal year 2025 outlook in more detail. Gerald.

Thank you, Frank, and thank you everyone for joining us today. I'm going to go through a more detail on Brooker second quarter. And first, half 2025, financial performance, starting on slide 11.

In the second quarter of 2025, our results came in below our expectations on both the top and bottom lines.

In the second quarter of 2025, Bruker reported revenue decreased 0.4% to $797.4 million, which reflects an organic revenue decrease of 7% year-over-year.

to 3.7% to our top line, while foreign exchange was a 2.9% tailwind, resulting in constant exchange rate revenue decline of 3.3% year-over-year.

Geographically and on an a year-over-year, organic basis in the second quarter of 2025, our America's Revenue declined, in the low, double digits percentage.

European revenue also declined in the low double digits percentage, while Asia-Pacific revenue grew in the low single digits percentage, despite a low single digit decline in China.

For our IA region, revenue was up by a single-digit percentage.

BSI organic revenue declined 7.2% in the second quarter of 2025, with organic declines in all groups.

CSI systems declined roughly 10%, and BSI aftermarket revenue was flat or organic year-over-year.

Performance in the BSI segment was down organically in the high, single digit percentage year-over-year with softer academic Government, research orders, in most geographies and a significant decline in biofarma orders in the US.

Gap gross margin decreased 270 basis points to 48.6%.

Q2 2025 non-gaap operating margin was 9.0% impacted by weaker volume leverage unfavorable mix tariffs and foreign currency.

On a non-GAAP basis, Q2 2025 diluted EPS was 32 cents.

Down 38.5% from the $0.52 we posted in the second quarter of 2024.

Our EPS performance was significantly impacted by the decline, in the US dollar in the quarter, which resulted in a 6 Cent headwind.

Or 9 Gap. Um, the effective tax rate was 23.6% compared to 28.4% in the second quarter of '24, with the decrease driven mostly by favorable discrete items in the quarter.

On a gap basis, we reported diluted EPS of 5 cents per share, flat compared to the second quarter of 2024.

Weighted. Average diluted shares outstanding in the second quarter of 2025 were 151.7 million and increase of 3.7 million shares from the second quarter of 24 result, from our follow on Equity offering in May of 2012 24.

Slide 12 shows Bruker's performance for the first half of 2025, which has similar drivers to the second quarter.

Turning to slide 13. Now, during the first half of 2025, we had a decrease in operating cash flow of $85 million, driven principally by the timing of tax payments and other items, with a modest year-over-year increase in capital expenditures in the first half of '25, which resulted in a free cash outflow of $110 million in the first half of '25.

Given the challenging market conditions, today we announced the expansion of current cost-saving initiatives intended to take $100 to $120 million of annualized costs out of the business.

These actions cross all business units, all geographies and all functions. Within buger, this expanded cost program is already underway but the majority of savings is expected in fiscal year 2026. These cost actions are expected to contribute. Approximately 300 basis points of operating margin Improvement in fiscal year 26 even under flat or muted market demand conditions.

Turning now to slide 15, we are updating our full-year 2025 outlook to reflect Q2 results and current market tariffs, as well as foreign exchange headwinds.

Our outlook for fiscal year 2025 now assumes revenue in a range of $3.43 billion to $3.55 billion, with an organic revenue decline of 2% to 4%.

Contribution from Acquisitions, is expected to be approximately 3 and a half percent. And we now expect a foreign currency Tailwind of 2 and a half percent on the revenue line.

This leads to updated reported Revenue growth guidance. In a range of 2 to 4% with approximately 0.5% constant exchange rate growth year-over-year,

For operating margins in 2025 given soft market conditions. We now expect lower organic revenues. Expected m&a dilution and tariff on Foreign Exchange headwinds to lead to an approximately. 210 basis point decline in operating margins year-over-year,

And decline consists of headwinds of 40 basis points, from 2024 m&a activity.

60 basis points from tariffs.

90 basis points from foreign exchange as well as a 20 basis. Point decline in organic operating margin

On the bottom line, our updated fiscal year 2025, non-gaap EPS is expected to be in a range of 195 to 205, which implies non-gaap EPS down 15 to 19% compared to fiscal year 24.

and expected fiscal year 25 with the present, trough in global academic, biofarma drug Discovery, and Industrial Research, instrument markets,

As well as a higher foreign exchange headwind than previously, expected of an of an additional 5 cents.

We expect a very significant EPS Rebound in fiscal year 26 based on our significant cost cutting initiatives with or without meaningful Revenue growth.

Other guidance assumptions are listed on the slide and our fiscal year. 25 ranges have been updated for foreign currency rates, as of June 30th 2025,

with respect to the third quarter of 2025, we expect relatively weak, organic Revenue performance again with mid to high single digits percent decline year-over-year in the third quarter of 2025

On EPS, we expect non-gaap DPS for the third quarter of 25 to be similar to EPS in the second quarter of 25, with a re acceleration of eps expected in the fourth quarter.

To wrap up Market, tariff and foreign exchange headwinds impacted our second quarter 25.

We remain cautiously optimistic about a fiscal year 26 partial recovery and research instruments and are very committed to significant margin expansion in EPS growth in fiscal year, 26 and Beyond.

And with that, I'd like to turn the call back over to Joe. Thank you very much.

Thanks Gerald. We will now begin the Q&A portion of the call.

As a reminder, to allow everyone time for questions, we ask that you limit yourself to 1 question and 1 follow-up operator.

Thank you. You will now begin the question and answer session to ask a question. You may press start and 1 on your touchtone phone, if you are using a speaker phone, please pick up your handset before pressing the keys.

If at any time your question has been addressed and you would like to betray your questions. Please press start and 2 at the same time. We will pause momentarily to assemble our roster.

The first question comes from the line of Punnett soda with Ling Partners. Please go ahead.

Yeah. Hi. Um, I'm Frank Gerold. Thanks for taking my questions. Um, first 1 on the, uh, guide. I understand, um, the magnitude of cut. Um, but maybe just, uh, given the backdrop of the markets. Um, uh, could you parse out? Why is the backlog which has been strong? Why is that not helping? Uh, this year, you know, and how should we think about? You talked about book to build, but how should we think about the recovery here in the fourth quarter?

Given that's an important quarter for from an instrumentation perspective and then on fiscal 26 Gerald talked about um, a recovery there. How should we think about fiscal 26? I know. It's a bit early but I would love your thoughts there.

Thank you, Punnett. So, backlog, we are using our backlog to some extent. Obviously you can't um accelerated at will as as in delivery times production and delivery times are very much planned and locked in by the customers. Also our backlog has come down slightly from 7 months to 6 and a half months. So we are leveraging that using that

um,

yeah, we think it's actually our Q4 I know Q4 has a bit of a ramp, but we're actually feeling pretty comfortable with that with all of our financial planning. I think that that, that looks um,

Doable and um and and we as we as gel had caution Q3 we think will be still somewhat weak. Um a little too early to talk about 26. Uh we just wanted to make sure that even in the no growth scenario we can deliver very significant, margin expansion and EPS growth. Um, whether next year will be no growth or a partial recovery of a few percent growth. Uh we don't have the visibility yet and we hope to gain that in the next, you know, 1 or 2 quarters, obviously, a lot of things, a lot of moving pieces still, especially when it comes to US Federal budgets.

Got it. Um, and then on the UHF, um, magnets, uh, I didn't, um, apologize. If I missed this, I would love to know if you're expecting that in any third quarter or the fourth quarter. And there was a recent acquisition in the space of the BB assets, um, that channel, soaks your multi biotyper. Do you expect any impact to the maldi? Um, and the, the sales from that obviously, that's a lcms company. That acquired those assets,

um, so

Field. Um, we don't expect an ultra high field Revenue. Recognition in the third quarter, we do expect 1 in the fourth quarter.

On that topic. Um,

Then you're talking about the BD. Microbiology business being in an acquisition process. Is that what was? Yeah, so obviously we'll we please. Yeah.

Yeah, you know, I mean, when I I I don't know, uh, because obviously, if water is closest that in in early 26 it, you know, receive, we'll see what their intentions are. Um, keep keep in mind that in these Diagnostics businesses. The the quite honestly, the little benchtop multi-top that's 10% and 90% is the all all the essays, all the content, all the regulatory approvals, and all

So we can only, uh, observe that, when Dan or her, which has a sax Mass Effect divisions. When they acquired semen's microbiology, they continue to work with us on the on the Beckman culture, Diagnostics business in in in an excellent manner, going forward and and and

Words tempted by hey we can build a mass spec anybody can build a mass spec but a multi biotype of franchise that has worked extremely well with BD. Hopefully that will continue but we don't have any you know until that closes. Um,

We we we will, we will see in 26, I guess if, if someone if, if the if someone wanted to develop something like this, it would be a very, very large 5 year investment. And by that time, of course, we're moving on. So anyway, but, uh, it's, it would be speculative. Quite honestly, we don't expect it, but we, we, we don't know.

Got it? Okay, that's helpful. Thanks Frank.

I would point out that we obviously sell more than half of our multi bios ourselves directly. So, if at some point a channel was no longer available, I think we could handle that very well.

Thank you. Next question, comes from the line of Tyco Peterson with Jeffrey. Please go ahead.

Hey, thanks. Um, Frank. I want to push on the the cost out and and really the idea here is, you know, earning today are 30% below where they were 90 days ago, um, and then only 5 cents of that is is FX. Um, I know you're protecting the p&l now, um, but a couple things I guess why didn't, you know, you initiate some of these these cost out sooner and are you committing to the 100 to 120 million regardless? Even if the Top Line, uh, does start

To come back.

Good questions, Tau. So we did start earlier, we early in the year when be before any of the headwinds appeared. We had a we had an initial Savings Program where we just tried to grow our expand, our margins, more than what we had guided to initially, and we had planned an additional 25 million and you 25 million cost savings plan. We then win the terrorists, began to appear, we expanded that to 50 million plus, uh, in a second phase. And um,

Which is good because most of the cost savings are kicking in next year. But about 30 million of cost savings are kicking in, in our, in our part of our guidance, for fiscal year 25. So the bigger effect will be in 26 admittedly. But at least we do have 30 million about 30 million of cost Savings in our fiscal year 25.

To the last point. Taiko? Yes, we are.

Completely committed and dialing in for the $100 million to $120 million in cost savings. We hope to be at the upper end of that, and that's going to...

We expect that to happen, independent of market conditions or recovery. Um, if that gives us in a flat scenario 300 dips of margin Improvement. Next year, that's great. And if the growth comes back, we don't expect it to, you know, snap back fully but

Comes back partially wonderful. Then we can deliver more margin expansion and EPS growth. But we're completely committed to that. Yes.

Okay, and then on the growth side uh if I go back to our conference in in June you know you had effectively committed to 4% growth in 26. Now it seems like you're you're not wanting to go there. Maybe just talk about what has really changed, you know. In the past uh uh 2 months here on the growth side and then maybe just before I jump off 1 for Gerald on Leverage, you know, uh over 4 turns but the Covenant is 3 and a half turns. Can you maybe comment on that dynamic as well?

Okay, I'll take the first part.

so, we were

Indicating at your conference, um, that we didn't expect growth in '26 to come back to more traditional.

For us.

6 to 8% levels. And, and that, uh, at that point, we were a little bit more optimistic, that it might be, you know, maybe it wasn't a commitment to that, but we were speculating. It could be 2 to 4% organic growth next year. Um, what has happened is that some of that's expected, the US academic and China academic stimulus. Money is not flowing yet. Uh, that was somewhat expected and expected. I think when we saw you at your conference, um, the additional us biofarma weakness in orders, was

For high-end drug Discovery research instrumentation. I know, it doesn't hit all companies equally but for research instrumentation, we saw a significant slowdown there and we'll see whether once tariffs sell and and you know and and some of the other political settlements kick in whether that

Additional headwinds go away or abate in the second half of this year, and that will, of course, in part drive Q2. We also saw, because of the economic and tariff uncertainty, that certainly our interpretation saw general weakness in Europe, the U.S., and China.

In industrial research instrument Investments. So that was also something that became clear in the second half which is why we're more muted in our our we don't have growth expectations for 26 but we do want to be realistic and ready for a no growth scenario. That's not our expectation. We don't have an expectation yet but I want to make sure that we can do the the significant margin expansion and double digit EPS growth even without growth. But please my words are even without growth. We hope for some modest growth a partial recovery. We don't know. We don't we cannot give guidance for 26 of what that might be.

Integral on your question regarding leverage ratio. We don't comment specifically on ratio dynamics quarter by quarter. I mean, I can't tell you that we have satisfied our debt covenants for the first and second quarters of 2025.

And we have a Target is I think we've discussed um directly um in around that 2.7 range and that's what we're working towards over several over yeah over 7 probably years so yeah.

Thank you.

Sure.

Thank you. Next question comes from the line of Brandon Kuyat with Wells Fargo. Please go ahead.

Gerald, just follow up there. Did you unpack the free cash flow burn in the second quarter? How much, how much was 1 time and uh, what's your, what are you expecting for? Operate, cash flow in the second half. And why is it capex coming down by a larger degree?

Sorry, I wasn't sure. I caught the last part of your question. How is the capex coming down? Why is the capex? Yeah, I think our capex. Let me just ask the last part of your question. For the capex is plan to to scale down. We have dialed that back for the third and the fourth quarters. I mean, we do typically have programs that are already in motion for the first and second quarters. And that, that's why you see the capex levels where they are, um, yeah and and on the cash flow burn. Yes. We did have a couple of so that what I would describe as unusual. Um outflows in the second quarter related specifically to some tax payments which we highlighted and those we don't expect to recur. So those will we expect to get back to a normal cash flow and brand. Now those were those were sizable. Those were 50 to 60 million including some uh tax payments for um that are prepayments some of which we expect to recover. But yeah, there were some sizable tax payments in that second quarter.

Okay, so then Frank, I think Gerald said BSI aftermarket was flat in the quarter. Can you kind of unpack what you saw between Diagnostics and maybe some ANg customers? It's just surprising to see, you know, the aftermarket utilization kind of flat in the quarter. Thanks.

That granularity we do not have. Um,

Obviously the Diagnostics business has been growing very nicely, sort of according to plan although placements uh for the elitech molecular Diagnostics business which you don't see in Revenue.

Doing great and in terms of uh, growth and margin expansion, it's according to plan so that that gives an indirect a partial answer to what you're saying, namely there, of course 80% or 90% consumable space and they, they are as well as the multi biotype or consumables are doing well. Um, therefore aftermarket, in other segments was was, was also down partially but we don't have granular percentages on that.

Hope that helps.

Mrad, are you done with the question?

Yeah, great thanks.

Thank you.

Next question comes from the line of Luke seegott with Park list. Please go ahead.

Great, thanks. Um, just wanted to talk a little bit about the underlying dynamics. As you think about that more muted growth in 2026, you know, particularly around China, because we've heard from peers right now that they're starting to see some of the stimulus flow through. So have you guys started to see any of that? And then as you think about those dynamics in 2026 or more muted growth, um,

And also, following up here on Tao's question. But kind of, you know, is that is that just assuming the current market environment, just continues there, just trying to figure out like, if if China should start getting better, what would, you know, in that in that more muted? Growth scenario? What's getting worse?

well a muted growth scenario in our maybe we ah a muted growth scenario, still a growth scenario right now we're seeing a decline in our in in our scientific and and Industrial and biofarma research markets

So a muted growth scenario, even a no growth scenario, next year would be better than the headwinds that we're observing right now.

We don't mean a muted growth scenario, meaning a decline next year, at least at this point. That's not what we're anticipating.

So maybe with that clarification.

We also do not, you know, expect a market growth or, for us, you know, a 6% to 8% organic growth snapback next year.

Hopefully we'll get there by 27, but you know, let's not comment on that one right now. China stimulus for high-end research instrumentation. We have not seen those releases yet.

We've seen reasonable 10 directivity in China lately, including into July, but that wasn't necessarily the high-end stimulus funding. There was just normal China activity, which maybe is getting a little bit stronger.

Um our Chinese customers that are looking for shovel ready, large projects in you know that include NMR and mass spec and lime and high-end microscopes remain very optimistic that this is just a question of time until the province is released it. Perhaps once you know

There is greater Clarity or maybe there is greater Clarity that there may not, that there's probably isn't going to be an all-out China us, trade War. During that time, we think the province is held back to to see whether they needed a rainy day fund. Anyway. Um so China stimulus is not released yet for our high-end research instrumentation and remarkable optimism by the customers that it's going to happen. We just don't know exactly. When we do also expect that as tariffs settle in and the new economic world order has is emerging uh, for trade that, um, CFOs in major industrial. And, and biofarma companies will be less reluctant, to release capex Investments because they do need the research capabilities, whether it's industrial materials, semiconductor, or of course, drug Des.

Covering. So in that sense, we expect an improvement in 2026 compared to 2025, but we cannot quantify it at this moment.

Having said all of that, and we don't want to rely on that improvement, even with no growth, we expect to deliver a margin improvement of $300 million or greater. That's.

The same way. Okay, great. Thanks. And then for follow-up.

When you're, we talked about this a little bit before about with the the NIH and the or the US academic funding issues. Um, you know, and how you ultimately kind of see this shaking out where whether it's a more of a democratization from the from the coast or from the IVs or the high, you know, the high.

How do you kind of see this ultimately playing out with the funding releases and, you know, over the next few years?

We have we can read some tea leaves. Yeah, so I think I I don't think NIH budgets will be flat or up. I don't think they'll be down 40% either ditto for NSF or or, you know, doe research or so they'll we assume that the deal will be that they'll be down. And now we're

If they're down 20%, that's not unrealistic from what we're expecting, but maybe they're only down 10%. We shall see.

So that's uh at the bigger picture, the other Trend that you've mentioned, that this is not only temporarily but longer term.

You know, going to be a More Level Playing Field away from the coast or or or also Investments that aren't, you know, primarily in Massachusetts, and Northern California. Um, I think that Trend political Trend. I continue to see that. So I think some very, you know, excellent universities elsewhere. Um, all may may may be able to get a bigger piece of the pie and this is even after some of the

Already announced and potentially pending settlements of the government with some very well-known universities.

Um, we do see

NSF for 2025 is calling for some final presentations on Big Ticket, NMR items. I don't know what they will do with that and whether there is then 2025 funding that may still come through. Even while we're mostly focused on 2026 budgets, there are some encouraging signs. A couple of things went through with NIH budgeting, and the customers got ordering from us two days later. Um, but it's not needle moving yet. So it's early days, and we don't have clear visibility yet. There are some signs that maybe the worst of the academic funding crisis.

could be over soon, but we do not expect the snap-back to the full growth rate. So we had previously.

Great. Thank you.

Thank you. Next question comes from the line of Super.

Nambi with Google n, please go ahead.

Hey guys, I had a question on the 2025 guide itself. If the cost savings aren't hitting until 2026 and the headwind to EPS is getting worse with FX, how are you thinking about the second half? Just given the soft orders in the quarter.

Um, super good question. So, we do think that of our cost savings for the full year, about $25 million to $30 million of cost savings will kick in and will benefit us this year. They're being overwhelmed by the headwinds from, um,

You know, from the previous M&A, from the organic decline of 2% to 3%, 2% to 4% that we're now projecting, as well as currency and tariffs, um, but, you know, they are meaningful. Um, that just to a bigger—they're kicking in to a much greater extent than in 2026. And, of course, we've only recently, within the last...

Several weeks have expanded our cost-cutting initiative very significantly and more than doubled it from what we had previously planned to counteract. And tariffs did that answer your question, or did I miss something? Super.

Um, no, that did Frank. I was just hoping for some more grandeur in terms of the bridging between revenue and EPS to hit the Q4 ramp, but partially definitely answered the question.

2 boot. It's Gerald. I'll just add, you know, Frank's reference to that $30 million. The bulk of that is going to hit for fiscal year 2025 in the fourth quarter. So we're, and then the remaining, the larger majority of it is going to hit in fiscal year 2026. So we are seeing some improvements in our guidance expectations around the fourth quarter versus the third quarter. Um, just to help you with respect to that.

Okay, thank you guys.

Yeah.

Thank you. Next question comes from the line of Dan Breen with TD Cowen. Please go ahead.

Great. Thank you. Uh, thanks for the questions. Um, maybe just on Na Tranq and Gerald. Um, thank you. You're obviously the...

The 2003 land in 2026, but I think there's been more optimism. I think there's been raised here, given the SIM and appropriation saying, up 1%, and folks think that, you know, a CR could be likely. So I'm just wondering when you think down 10 to 20.

Kind of a, what's the mechanism to get there and be? If things were better, would you expect your customers would spend that money? Or what does your commercial team think about? Would they be reticent, just giving, you know, revisions and things like that?

Oh um so the 10 to 20% I want to be I don't have an expectation. I I there's been too many surprises to have an expectations of fiscal year. 26 budgets. I know I I know the senate committee marked it up and had a small increase.

And the administration was initially setting for a 40% decrease. I just want to be prepared for NIH budgets being down 20%.

For Q2 2025, we expect continued delivery of margin expansion.

Um,

For.

This year, fiscal year 2025, we expect the U.S. academic government,

To be down 20% to 25%. That's what we said last quarter already. So this is a fiscal. This is our

Calendar year 25.

Um, and that that plays out about, as we said, so far, it's down about minus 15 for the first half of the year. And so, by, for the full year, 25 calendar year for us, uh, Cadet us Academia being down, 20 to 25% seems like a realistic expectation. I think we hit. I don't think it's going to be worse than that. So funding is still flowing. And then for next year, as I said, I have no predictions. I've stopped making predictions there. I just want to be prepared for a 20 for a 20%, fiscal year. 26, government fiscal year, 26 NIH, budget reduction. And if it's better than that, I'll be delighted and we can, you know, more can flow through our

bottom top and bottom line in 26.

Great customer. I think customers will spend in a heartbeat if they get grants. They can't give the grants to the Gen, to the university. So our, you know, struggling otherwise financially, when they get specific grants, I think they'll order in a heartbeat.

That's great. Thank you. And then maybe just one on the backlog and kind of bookings. Obviously, the bill has been a week now for I think four or so quarters. Can you just remind us?

In a given year, what percent of your revenue growth comes from that backlog? What's book and bill? I think there's been some concern, like could Bruker even grow in '26, just given you that four consecutive quarters of weak bookings? The bills, but obviously bookings turn up and that would support growth. So can you just walk through a little bit of the, you know, kind of the visibility and the mix between conversion and kind of new turns? Thank you.

Yeah, I mean, you know, um, we we now have aftermarket consumable service software of more than a billion. So it's become a significant, you know, it's it's become a meaningful part of Brooker, that, of course, you know, tends to flow turn into Revenue pretty much in the quarter when it gets when it gets ordered. Um, we also have smaller, you know, benchtop and you know, the sub hundred thousand dollars scientific instruments that very often, you know, achieve Revenue in in the same quarter within 2 or 3 months after they get after they get ordered. Uh so some things maybe maybe you know there's some part of our Revenue that turns more quickly and then there's of course some Revenue where sometimes, you know so

Rep order to revenue can be 18 to 30 months or so, so we have that.

Mix. Um,

So our backlog is still elevated at 6 and a half months. Uh this is the BS, this is the backlog of 6 and a half months, we expect that eventually to level out with a new mix. As we have more consumables, more elitech and things like that more. Now we added some metabolomics. Consumables and some therapeutic drug monitoring consumables with some recent smaller Acquisitions. So we expect that 6 and a half months eventually to go down to about 5 months of backlog as a new normalized level. So we still have some cushion from backlog for the second half and for next year, but of course, we also need the bookings.

Got it. Great. Thank you, Frank.

Thank you. Next question comes from the line of Patrick Donelli, a city. Please go ahead.

Questions. Um, Frank or Joe, can you press a little more on the second half? Cadence, the $4, you step up, still seems pretty steep. I mean, if you're talking about Q3, looking at similar earnings, call it $0.32.

It implies around $0.90 in Q4.

And again, the revenue kind of stepped up with that. So, I just want to talk through the visibility into that Q4 number. It did sound like things are maybe getting a little more challenging at the end of the quarter. So, can you just talk about the visibility and confidence in that Q4 ramp?

Yeah, Patrick. It's Gerald, I'll take this. And Frank may want to add some more color. So just generally in terms of the, um, this the scaling or graduating this end to the fourth quarter as you already know, our fourth quarter is, is really not a quarter. It tends to be more like a 30% of the, um, a number on an annualized basis. So we do see, um, a more significant ramp historically. And I, we have no reason to believe that that will not happen for 2025 and fundamentally. I, I would also say, as I mentioned earlier, in the comment to subu, we do have some cost savings that are going to get kicked in to the fourth quarter that's already planned, um, and scheduled. So we're pretty confident that you're going to see a pretty significant lift in the um in the operating margin and EPS performance for the fourth quarter, I think your math as usual. Patrick is not

Not terribly far off from what our estimates are for the fourth quarter. So, that's kind of the, uh,

I'd say at a high level.

Our expectations are still some flat down. Um, you know, Revenue growth for the fourth quarter, given the market conditions, but improved profitability given the scale we get. As you already know, we get significant in a leveraged down to the bottom line on higher volume. And the expectation is and this is just typical for us. We do have pretty huge, fourth quarters and every year we do and and and then some often it's even better than what we had anticipated. It's our fourth quarter pattern. So we feel comfortable with the Cadence. Yeah.

2 more questions, perhaps? Yeah, yeah, sure.

Thank you. Next question comes from the line of Josh Waldman with Cleveland Research. Please go ahead.

Morning guys, thanks for taking my questions, uh, 2 for you first. Frank on, on the academic side, I think Gerald mentioned, softer, academic orders in most geographies. Um, I wondered if you could comment on what you're seeing in Europe, um, is that market getting worse on the academic side or and I guess more broadly are there other geographies that uh, step down unexpectedly and then within the US, uh, academic environments, uh, wondered if you could talk on the timing of potential revenue recovery, I mean, how long would it take to

Kind of work through the software order book.

To flush this kind of line through the revenue side.

Okay, on the academic side.

When looking at the academic side, when would you need to see a recovery in orders for that to show up in revenue? And does it hit 27? Yeah.

Yeah. Um, so clearly on the old academic orders, the two bad guys are the U.S. and China for us. Um, that's where we have the most pronounced, you know?

Reduction in orders in the first half uh from the academic from the academic and academic medical research Market. Um

Europe, rest of APAC. You know that just fluctuates up and down. There's really no no Trend that's discernable there. Uh, Q2 wasn't strong. I'll uh, but but I don't I I think that's if you look at it then over several quarters, then then uh, it's it's the US and China that that I think are crucial and academic side.

How long would well? Obviously with less backlog we can now do faster deliveries. Um, so they are some some products ultra high fields and a more or very large you know, stem microscopes or so that indeed sometimes take 1 or 2 years to deliver. Um but um,

It’s a 26-story. Um, even if orders came in and...

August, September, and I don't expect a lot of, you know, I don't like expect that necessarily. There could be some U.S. orders that come through before the end of our fiscal year at the end of September. There's a possibility of that.

26, I don't think there is any step up to be expected in Q2 any more.

Got it. And then Frank, on tariffs, I'm curious if you think you're seeing tariffs negatively impact your competitive position in new opportunities at all. You know, I'm thinking on the price or surcharge front. Does it seem like customers are either holding off on placing orders because of price increases, surcharges, or maybe even looking into other suppliers?

Yeah, uh, if I look at each of our market segments, you know, in Q2 2025...

Spatial, biology main competitors us. Where us NMR main competitor is Japanese. We're European Union, ended up at a Level Playing Field with a new tariffs.

In Mass Spec, a lot of the other aspect companies manufacture in Europe. Also in Germany in Singapore, Etc. So, uh and and, and you go down the line x-ray, Etc. It it turns out it turns out that there hasn't been a significant Distortion. Um,

Competitively, from the new, uh, from the new pics from the new tariff picture. Um, again, we're still observing Switzerland; that's obviously somewhat of a pathological number at the moment. We expect that to be less and maybe be more in line with what we have in Europe or from Malaysia.

And, by the way, in NMR and MRI, we have the most flexibility to say, okay? I mean, almost immediately, we could turn on a dime and say any of these systems for the US market come from Germany or from France, where we have large fifth factories. So, there we could move very, very quickly. If come August 7th.

That Swiss number was still extraordinarily high for a while. So

So so the short answer would have been. We think it's we think there is a know, it can no competitive shifts based on that, it's just the cost headwind.

All right, so I have one more question, and then we'll wrap things up for today. Um,

Thank you. Next question comes from the line of Rachel, wet install with JB Mark. Please go ahead.

Um, hello, this is Marcus and we're on Rachel from JP Morgan. Uh, thanks for taking the question. I just wanted to clarify your comments on Paris. Just now, what are you assuming in your guide for this was terrorists? At this point? Are you assuming 39% or something lower? And then, perhaps, you brought more broadly, if you could give more color on your updated tariff assumptions, given the changes in Swiss terrorists, but also European terrorists.

Thank you. Yeah. We're, we're, we're, we're, uh, for European union and Israel. We're at 15%. We're Malaysia. We're at 19% Switzerland. We're presently modeling at 15%. Um, in a worse case scenario that we didn't shift supply chain and it was 39%, that could be an additional 10 million. Hit that we presently don't have here, but we think that's just not going to happen. Ah, we think the number will be lower and be in that case. Uh, we will just not ship from Switzerland. We will build our nmrs and, uh, which is primarily an NMR story, um, in, uh, and, and make them in Germany or France.

So that's why I think our modeling is appropriate.

Thank you.

Thank you. This concludes our question-and-answer session. I would like us to turn the conference back over to Joe Kostka for closing remarks.

Thank you for joining us today. Bruker's leadership team looks forward to meeting with you at an event or speaking with you directly. During the third quarter, feel free to reach out to me to arrange any follow-up. Have a good day.

Thank you. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.